A Closing Thought

Articles

The responsibility of increasing diversity falls on every stakeholder in the clinical trial value chain.

Population Representation: Everyone Must Play a Part 

Vice President, Sites and Patients Center of Excellence, PPD Clinical Research, Themo Fisher Scientific

DCTs and RWD among topics for industry to focus on moving into 2023.

Lessons Learned in 2022 and the Impact on Drug Development in the Year Ahead

Assistant Professor in Medical Informatics at Amsterdam University Medical Centers and a Product Owner at Castor

Study shows more support is needed for clinical teams to ‘FAIRify’ their data.

The State of Data FAIRification in Clinical Research

Chief Delivery Officer, Data Services at eClinical Solutions

Accelerating trends in clinical data are forcing changes in strategy.

What the Future State Really Looks Like for Clinical Data Leaders

COVID spotlights the troubling disparity in clinical research representation. How can we remove these barriers?

Clinical Research Needs Greater Participant Diversity

Partner and Co-Chair, IP Litigation Group and Diversity, ArentFox Schiff LLP

How the digital environment can transform drug development space.

R&D Using the Metaverse and Digital Twins

The only way for pharma companies to know where to focus their COVID-19 R&D efforts is for the industry to have access to real-time, real-world evidence of what’s working to keep people alive, write Travis Leonardi and William Kirsh.

Drug Development in Wartime: Driving Tomorrow's R&D Decisions with Today's COVID-19 Data

The need for statisticians, mathematicians, and computer and data scientists to collaborate on modern methods
for “substantial evidence” in drug development is critical.

Pandemic Highlights Urgency for New Methodologies for Evidence Generation

The evolving challenges and new opportunities from the latest wave of change in clinical data management practice.

Data Management Landscape is Still Changing, Are We Adapting Fast Enough?

Organizations that continue to disregard the technological needs of one of the industry’s core audiences run the risk of having their trials ignored.
